
Please try another search
ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company that develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, pancreatic cancer, Parkinson’s and Huntington’s disease, atherosclerosis, Alzheimer’s disease, and obesity. The company has a license agreement with L&F Research LLC, and InflamaCORE, LLC. ZyVersa Therapeutics, Inc. was founded in 2014 and is based in Weston, Florida.
Name | Age | Since | Title |
---|---|---|---|
Harold E. Bays | - | 2024 | Member of Scientific Advisory Board |
Stephen C. Glover | 65 | 2022 | Co-Founder, Chairman, CEO & President |
Alessia Fornoni | - | - | Member of Scientific Advisory Board |
Pablo A. Guzman | 75 | 2023 | Chief Medical Officer, Senior VP of Medical Affairs & Chairman of Renal Scientific Advisory Board |
Sharon G. Adler | - | - | Member of Scientific Advisory Board |
Helen Bramlett | - | - | Member of Scientific Advisory Board |
Robert G. Finizio | 54 | 2022 | Independent Director |
Robert W. Keane | - | - | Member of Scientific Advisory Board |
Marlene Haffner | 84 | - | Member of Scientific Advisory Board |
Juan Pablo de Rivero Vaccari | - | - | Member of Scientific Advisory Board |
Min-Chul Park | 43 | 2022 | Independent Director |
James R. Sapirstein | 64 | 2023 | Independent Director |
Richard J. Glassock | - | 2023 | Member of Renal Scientific Advisory Board |
Fernando C. Fervenza | - | - | Member of Renal Scientific Advisory Board |
Daniel Cattran | - | - | Member of Renal Scientific Advisory Board |
Gregory G. Freitag | 63 | 2023 | Independent Director |
W. Dalton Dietrich | 72 | - | Member of Scientific Advisory Board |
Suneil Koliwad | - | 2024 | Member of Scientific Advisory Board |
Marc-Andre Cornier | - | 2024 | Scientific Advisory Board |
Caroline M. Apovian | - | 2024 | Member of Scientific Advisory Board |
Samuel Klein | - | 2024 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review